<i>Candida auris</i> Testing by the Antimicrobial Resistance Laboratory Network, United States, 2022–2023
During 2022-2023, the Antimicrobial Resistance Laboratory Network tested 8,033 Candida auris clinical isolates in the United States. Overall, 95% of isolates were fluconazole resistant, 15% amphotericin B resistant, and 1% echinocandin resistant. Laboratory capacity for C. auris identification and antifungal susceptibility testing is essential to address this emerging public health threat.
Authors
- Dawn Sievert
- Jessica Laury (ORCID: https://orcid.org/0000-0003-4578-0488)
- Sophie Jones
- D. Joseph Sexton
- Shawn R. Lockhart
- Elizabeth L. Berkow
- Jeremy A.W. Gold
- Meghan Lyman
Publication Details
- Journal
- Emerging infectious diseases
- Published
- 2026-02-01
- DOI
- https://doi.org/10.3201/eid3202.251043
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.00